After being treated to NSCLC tumor-bearing in vivo models, the EGFR-targeting PROTAC exhibited a better tumor growth suppression effect than gefitinib, promoting the migration of CD3-positive T cells to tumor tissues. Here, EGFR is linked to neoplasm.